-
Mineralys Therapeutics NasdaqGS:MLYS Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Location: 150 N. Radnor Chester Rd., Radnor, PA, 19087, United States | Website: https://mineralystx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
677.6M
Cash
343M
Avg Qtr Burn
-48.17M
Short % of Float
16.57%
Insider Ownership
1.46%
Institutional Own.
99.62%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lorundrostat Details Hypertension | Phase 3 Update | |
Lorundrostat Details Chronic kidney disease, Hypertension | Phase 2 Data readout | |
Lorundrostat Details Obstructive sleep apnea | Phase 2 Update |